This phase Ib trial tests the safety, side effects, and best dose of iberdomide in combination with teclistamab in treating multiple myeloma that has come back after a period of improvement (relapsed) or that does not respond to treatment (refractory). Iberdomide is a medication that belongs to a group of drugs known as cereblon E3 ligase modulators. Iberdomide works by targeting and destroying proteins that help myeloma cancer cells to survive. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as teclistamab, may help the body's immune system attack the cancer, and may interfere with the ability of cancer cells to grow and spread. Giving iberdomide in combination with teclistamab may be safe and tolerable in treating patients with relapsed or refractory multiple myeloma.

Start Date08 Jul 2025

Sponsor / Collaborator

National Cancer Institute

NCT06762769

/ Not yet recruitingPhase 2IIT

Isatuximab and Iberdomide As Immunotherapy for High Risk in Smouldering Myeloma

The study will test a new combination of 3 drugs: Isatuximab (Isa), Iberdomide (Iber) and Dexamethasone (Dex), in patients who have intermediate or high risk smouldering myeloma. Smouldering myeloma is an early form of myeloma which may progress to active multiple myeloma, but at a slow rate. Patients with smouldering myeloma do not usually receive any treatment but will have regular check-ups and observation. Some patients have a diagnosis of smouldering myeloma which has a higher risk of progressing to active myeloma.
The study will test if the combination of drugs is effective at preventing or delaying the disease progressing into active multiple myeloma. The study will also test if the combination is tolerated and accepted by patients.

Start Date31 Mar 2025

Sponsor / Collaborator

University College London

[+2]

NCT06785415

/ Not yet recruitingPhase 1/2IIT

Phase 1/2 Trial of Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for Relapsed Multiple Myeloma

This phase I/II trial tests the safety, side effects, and best dose of iberdomide and how well it works in combination with daratumumab, elotuzumab, and dexamethasone in treating patients with multiple myeloma that has come back after a period of improvement (relapsed). Immunotherapy with iberdomide, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Daratumumab is in a class of medications called monoclonal antibodies. It binds to a protein called CD38, which is found on some types of immune cells and cancer cells, including myeloma cells. Daratumumab may block CD38 and help the immune system kill cancer cells. Elotuzumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Dexamethasone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response to help lessen the side effects of chemotherapy drugs. Giving iberdomide in combination with daratumumab, elotuzumab, and dexamethasone may be safe, tolerable and/or effective in patients with relapsed multiple myeloma.

Start Date03 Mar 2025

Sponsor / Collaborator

Mayo Clinic

100 Clinical Results associated with Iberdomide

100 Translational Medicine associated with Iberdomide

100 Patents (Medical) associated with Iberdomide

Literatures (Medical) associated with Iberdomide

01 Nov 2024·Clinical Lymphoma Myeloma & Leukemia

Cereblon E3 Ligase Modulators Mezigdomide and Iberdomide in Multiple Myeloma

Review

Author: van Rhee, Frits ; Patel, Tanvi H ; Al Hadidi, Samer

Multiple Myeloma (MM) remains a challenging hematological malignancy despite significant advancements made during the past 2 decades. Outcomes have improved by incorporating immunomodulatory drugs, proteasome inhibitors, and anti-CD38 monoclonal antibodies into treatment algorithms that include high dose chemotherapy and autologous hematopoietic stem cell transplantation. However, many patients may eventually relapse despite these innovations. Newer therapies targeting B-Cell Maturation Antigen (BCMA) offer promise for patients with relapsed or refractory disease. BCMA-targeted therapies carry notable side effects, necessitating vigilant monitoring and proactive infection prevention measures. They can also induce considerable immunosuppression, attributed to lower levels of immunoglobulins and increased susceptibility to infections. There is still a need for alternative treatment options with different mechanisms of action that can be easily administered and have a better safety profile. In addition, pomalidomide only overcomes lenalidomide refractoriness in a subset of patients. This review aims to explore 2 next-generation cereblon E3 ligase modulators (CELMoDs), Mezigdomide (CC92480), and Iberdomide (CC-220). We will discuss the biological aspects of these agents, including their mechanisms of action, efficacy, and toxicity profile, and provide a comprehensive review of current literature. Special attention will be paid to ongoing and future clinical trials that provide insights into the potential of these novel therapies in the management of MM.

01 Nov 2024·Cell Reports Medicine

Degradation of IKZF1 prevents epigenetic progression of T cell exhaustion in an antigen-specific assay

Article

Author: Tan, Sin Lih ; Mele, Deanna A. ; Mele, Deanna A ; Bommakanti, Gayathri ; Brucklacher-Waldert, Verena ; Criscione, Steven ; Doshi, Aatman S ; Kurasawa, James ; Buenrostro, Jason Daniel ; Tay, Tristan ; Doshi, Aatman S. ; Gorthi, Aparna ; Karapa Reddy, Iswarya ; Zhang, Ruochi ; Overstreet, Michael Glen ; Prickett, Laura ; Hu, Yan ; Jaensch, Elizabeth

In cancer, chronic antigen stimulation drives effector T cells to exhaustion, limiting the efficacy of T cell therapies. Recent studies have demonstrated that epigenetic rewiring governs the transition of T cells from effector to exhausted states and makes a subset of exhausted T cells non-responsive to PD1 checkpoint blockade. Here, we describe an antigen-specific assay for T cell exhaustion that generates T cells phenotypically and transcriptionally similar to those found in human tumors. We perform a screen of human epigenetic regulators, identifying IKZF1 as a driver of T cell exhaustion. We determine that the IKZF1 degrader iberdomide prevents exhaustion by blocking chromatin remodeling at T cell effector enhancers and preserving the binding of AP-1, NF-κB, and NFAT. Thus, our study uncovers a role for IKZF1 as a driver of T cell exhaustion through epigenetic modulation, providing a rationale for the use of iberdomide in solid tumors to prevent T cell exhaustion.

01 Oct 2024·JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Effect of iberdomide on cutaneous manifestations in systemic lupus erythematosus: A randomized phase 2 clinical trial

Article

Author: van Vollenhoven, Ronald ; Dörner, Thomas ; Schafer, Peter H ; Werth, Victoria P ; Schafer, Peter H. ; Korish, Shimon ; Merrill, Joan T. ; Werth, Victoria P. ; Merrill, Joan T ; Furie, Richard ; Li, Stan ; Lipsky, Peter ; Weiswasser, Michael ; Stern, Mark ; Delev, Nikolay

BACKGROUND:

Iberdomide, a cereblon modulator, promotes degradation of transcription factors Ikaros and Aiolos.

OBJECTIVE:

Evaluate iberdomide efficacy and safety in cutaneous lupus erythematosus (CLE) in a phase 2 study.

METHODS:

Patients were randomized (2:2:1:2) to iberdomide 0.45 (n = 81), 0.30 (n = 82), or 0.15 mg (n = 42) or placebo (n = 83) daily while continuing background lupus medications.

RESULTS:

The mean (SD) baseline Cutaneous Lupus Area and Severity Index Activity (CLASI-A) score was 6.9 (7.0); 28% of patients had a score ≥8; 56% had acute CLE, 29% chronic CLE, and 16% subacute CLE. Mean CLASI-A improvement in patients with baseline score ≥8 was 39.7% for iberdomide 0.45 mg versus 20.1% for placebo at week 4 (P = .032), with continued improvement through week 24 (66.7% vs 54.2%; P = .295). Proportions of patients achieving ≥50% CLASI-A reduction from baseline at week 24 were significantly greater for iberdomide 0.45 mg versus placebo for patients with subacute (91.7% vs 52.9%, P = .035) and chronic (62.1% vs 27.8%; P = .029) CLE but not for the overall population (55.6% vs 44.6%) or patients with baseline CLASI-A ≥8 (66.7% vs 50.0%).

LIMITATIONS:

Small patient subgroups of CLE subtypes.

CONCLUSIONS:

Iberdomide showed beneficial effects when added to background lupus medications in patients with subacute and chronic CLE.

News (Medical) associated with Iberdomide

04 Dec 2024

·www.prnewswire.com

Stay Ahead in Hematology: Strategic Competitive Intelligence for Informed Decision-Making | DelveInsight

A case study on how a leading pharma company in hematology turned to DelveInsight for long-term competitive intelligence support. DelveInsight provided an in-depth analysis of competitive activity in key hematological malignancies, helping the company stay ahead of the competition. LAS VEGAS, Dec. 4, 2024 /PRNewswire/ -- DelveInsight, a leader in healthcare competitive intelligence and consulting, released a case study on Competitive Intelligence in the Hematology Domain. A Europe-based client approached DelveInsight to evaluate a long-term partnership for insights supporting their clinical, commercial, and launch strategies for a novel oncology product targeting acute myeloid leukemia (AML), multiple myeloma, and acute lymphoblastic leukemia (ALL). The client sought detailed intelligence on competitive activity, class-wise market trends, launch estimates in countries of interest, and regulatory landscapes to inform their development and commercialization plans. An additional request for the segregation of mutation/protein expression-specific therapies was also taken into consideration. DelveInsight provided timely, in-depth analysis of the competitive landscape, emerging therapies, and regulatory situations across multiple countries. This enabled the client to make informed decisions on clinical development, market positioning, and commercialization, helping them stay ahead of the competition in the hematology space. With hundreds of thousands of new cases diagnosed annually, hematologic cancers, such as acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), and multiple myeloma, among others present a serious global health challenge while also opening doors for breakthroughs in targeted and personalized treatments. These cancers affect the blood, bone marrow, and lymphatic system, and often require aggressive therapies due to their rapid progression and complex nature. AML and ALL are particularly aggressive, with AML being one of the most common forms of leukemia in adults and ALL affecting both children and adults. Innovations in precision medicine and immunotherapy are transforming hematology, with CAR-T therapies showing promise for leukemias and CELMODs, like Iberdomide, emerging as potential successors to REVLIMID for multiple myeloma. Bristol Myers Squibb's collaboration with Karyopharm on mezigdomide highlights the growing focus on CELMODs. Additionally, FDA-approved therapies like CARVYKTI and TECVAYLI, along with ongoing advancements in bispecific antibodies and proteasome inhibitors, are reshaping the multiple myeloma treatment landscape, despite safety, cost, and manufacturing challenges. The market is rapidly evolving, with new therapies continually entering the pipeline. Several companies, including Bristol Myers Squibb, Celgene, Arcellx, Novartis, Regeneron Pharmaceuticals, Cartesian Therapeutics, Heidelberg Pharma, BeiGene, CARsgen Therapeutics, C4 Therapeutics, AbbVie (TeneoOne), Roche (Genentech), Pfizer, Agios Pharmaceuticals, Jazz Pharmaceuticals, Astellas Pharma, Novartis Oncology, Daiichi Sankyo, AstraZeneca/Astex Pharmaceuticals, Chimerix, Takeda, Rafael Pharmaceuticals Inc., Delta-Fly Pharma, GlycoMimetics Incorporated, BerGenBio ASA, MacroGenics, Syndax Pharmaceuticals, Arog Pharmaceuticals, Forma Therapeutics, Sellas Life Sciences Group, Autolus Therapeutics, Cellectis, Wugen, Servier, Allogene, and Precision BioSciences, are currently advancing the therapeutic landscape for hematological disorders. As research and innovation progress, there is renewed hope for improving survival rates and enhancing the quality of life for those affected by these challenging diagnoses. DelveInsight's Methodology for Competitive Intelligence in the Hematology Domain helped the client by: Comparative Analyses: Evaluating competitor products to identify strengths, weaknesses, and market positioning, enabling the client to understand where their product stands relative to competitors along with identifying the patient segment with high unmet need KOL Insights: Gathering opinions from Key Opinion Leaders (KOLs) on clinical development strategies, client's product acceptability scenarios, data presentation, probable uptake of their asset,, providing valuable perspectives to refine the client's approach. Current Treatment Paradigms: Analyzing existing treatment approaches to identify market trends, gaps, and unmet needs, helping the client position their product effectively in the market. In-depth Competitive Benchmarking: Assessing competitors' commercial launch preparedness, patient awareness campaigns, and pricing strategies to inform the client's product's market entry and competitive strategy. Market Intelligence: Providing insights into competitors' marketing, sales, and patient engagement approaches, guiding the client's commercialization and go-to-market strategies. Clinical Development Trends: Evaluating clinical trial timelines and strategies, tracking phase shifts in terms of probability of their entry into the higher phase, and analyzing trial data to anticipate future market shifts and inform strategic decision-making. Pricing and Access Strategies: Analyzing competitor pricing models and access strategies, allowing the client to make informed decisions on pricing and reimbursement for their product. Request a proposal to see how DelveInsight's Competitive Intelligence services can support your long-term strategic insights. How DelveInsight's In-Depth Competitive Intelligence in Hematology Helped Clients Stay Ahead in the Market Periodic Competitive Inputs: Provided regular updates on competitor activities, keeping the client informed of market shifts. Enhanced Market Awareness: Delivered ongoing insights into competitor strategies, enabling quick adaptation to market changes. Short-Term Strategies: Developed actionable strategies for immediate response to competitor moves. Counter-Messaging Design: Assisted in crafting counter-messaging strategies to address competitor claims and strengthen brand positioning. Positioning Refinement: Helped refine product positioning to gain a competitive advantage. Promotional Strategy Support: Offered recommendations on promotional tactics to boost market presence and attract key audiences. Why Choose DelveInsight? DelveInsight offers tailored, comprehensive competitive intelligence to keep your hematology product developmental and commercial strategy a step ahead. With expertise in AML, Multiple Myeloma, ALL, and other hematology domains, we support your clinical, commercial, and launch strategies with insights that matter. What Sets Us Apart: Timely Intelligence: Consistent, real-time updates on competitor activities, clinical shifts, and regulatory changes, ensuring you're never caught off-guard. Expert Analysis: From comparative assessments to pricing benchmarks, we provide actionable data that sharpens your positioning. Strategic Edge: We don't just offer data—we deliver strategic recommendations for counter-messaging, promotional tactics, and market adaptation. Choosing DelveInsight means partnering with a team dedicated to turning competitive intelligence into growth and success for your business. Transform your business with our case study. Schedule a call with our DelveInsight Business Development expert today! Conference Coverage Services : DelveInsight's Conference Coverage Services offer a thorough analysis of outcomes from major events like ASH, EHA, AACR, ESMO, ASCO, and others. This detailed examination provides businesses with essential insights for competitive intelligence and market trend forecasting, supporting the formulation of future strategies. Competitive Intelligence Services: DelveInsight's competitive intelligence services provide real-time, accurate insights across the pharmaceutical, life sciences, and medical diagnostics sectors, helping clients stay ahead in a dynamic market. With over 100 years of combined experience, our experts deliver actionable strategic insights, backed by robust research methodologies, to support critical business decisions and create a competitive advantage for our clients. Hematology Pipeline Assessment: Our hematology pipeline evaluation offers a comprehensive overview of cancer treatment options, clinical trials, and key areas within the hematological disorders field, all summarized in an accessible report format. The hematology-focused reports, available in our Report Store, provide in-depth insights into treatment strategies, mechanisms of action (MoAs), drug components, and launch plans for therapies in the late stages of development. This assessment enhances understanding of their launch timelines and strategic initiatives. R&D Analysis: Our skilled research and development analyst specializes in the complexities of hematology, offering essential insights and advice to clients aiming to advance in hematological research and development. They utilize a methodical assessment approach, aligned with industry norms, to track the progress of each hematology drug in both pre-clinical and clinical stages. DelveInsight's comprehensive hematological reports are crafted to reduce uncertainties and highlight overlooked areas, providing organizations with timely and strategic intelligence. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Contact Us Shruti Thakur [email protected] +14699457679 Logo: SOURCE DelveInsight Business Research, LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

ImmunotherapyASH

29 Oct 2024

·www.globenewswire.com

Starton Therapeutics Announces Notice of Allowance for U.S. Patent Application 17/518,930 “Continuous Delivery of Lenalidomide and Other Immunomodulatory Agents” Including Transdermal Administration

Significantly expands scope of patent coverage for Company’s proprietary drug delivery systems to now include transdermal deliveryPatent expected to issue from the pending application will have term extending to 2040, excluding any patent term adjustments or patent term extensions that may provide additional protectionSTAR-LLD is being developed for use in hematological malignancies which includes multiple myeloma (MM), chronic lymphocytic leukemia (CLL), and others. PARAMUS, N.J., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc. (“Starton” or the “Company”), a clinical-stage biotechnology company transforming standard-of-care therapies with proprietary dermal technologies, announced today that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application No. 17/518,930, covering STAR-LLD, the Company’s continuous delivery lenalidomide program. The notice of allowance for U.S. Patent Application No. 17/518,390, entitled, “Continuous Delivery of Lenalidomide and Other Immunomodulatory Agents,” includes claims directed to the delivery of immunomodulatory imide compounds including lenalidomide, pomalidomide, iberdomide, or a combination thereof with a transdermal delivery system. The Company’s previously granted U.S. Patent No. 11,197,852, covered drug delivery systems utilizing parenteral delivery by subcutaneous infusion. The allowed claims in this patent application significantly expands the scope of patent coverage by now including drug delivery systems that utilize transdermal delivery systems for continuous low-dose delivery profile of lenalidomide. “We are delighted to receive this notice from the USPTO, further expanding the protection of our continuous delivery lenalidomide program,” stated Pedro Lichtinger, the Company’s Chairman and CEO. “The transdermal delivery system that is the subject of the allowed patent application demonstrates our unique approach to lowering drug exposure and AUC (area-under-the-curve) to potentially improve efficacy and safety and demonstrate superiority.” The Company’s transdermal delivery system administers the immunomodulatory imide compound at a dose rate that is 10-75% of the daily dose of the oral and achieves blood levels of the compound that is equivalent to the blood level at a time point from 8 hours to 18 hours obtained from once daily oral dose. The transdermal application in the allowed claims of lenalidomide and other IMiDs is expected to obtain suitable blood levels which would equate to the continuous and low-dose levels of the subcutaneous administration in an easy to apply drug product. Once granted, the patent expected to issue from the pending application will have a term extending to 2040, excluding any patent term adjustments or patent term extensions that may provide additional protection. Starton retains full global ownership of the patent applications and granted patents with the technology and methodology being developed internally. About STAR-LLD STAR-LLD is a continuous delivery lenalidomide (LLD) in development to expand and replace the standard-of-care for the most common blood cancers, multiple myeloma (MM), and chronic lymphocytic leukemia (CLL). A preclinical proof-of-concept study for subcutaneous STAR-LLD demonstrated that MM tumors caused by human myeloma cells grew 25-fold if untreated, five-fold when treated with daily lenalidomide, and shrank by 80% with STAR-LLD over a single 28-day cycle. The study also showed a 100% overall response rate (ORR) using continuous delivery LLD and 20% of animals in this cohort were tumor-free after 100 days, compared to a 0% ORR in animals treated with a 70% higher dose of lenalidomide given in single daily doses. In addition, a Phase 1 bioavailability study in healthy men comparing subcutaneous STAR-LLD to Revlimid® demonstrated the drug is well tolerated and is >91% bioavailable by the subcutaneous route. It was also observed that the Cmax is <90% lower than oral Revlimid®. About Starton Therapeutics Starton Therapeutics is a clinical-stage biotechnology platform company focused on transforming standard-of-care therapies with proprietary continuous delivery technology, so people with cancer can receive continuous treatment to live better, longer. Starton’s proprietary transdermal technology is intended to increase the efficacy of approved drugs, make them more tolerable, and expand their potential use. To learn more, visit www.startontx.com. Forward Looking Statements All statements other than statements of historical facts included in this press release, including, without limitation, statements regarding our plans and objectives for future operations and expectations about current and future clinical trials, constitute “forward-looking statements.” Forward-looking statements are subject to numerous conditions and known and unknown risks and uncertainties that could cause our actual results or events to differ materially from those included within the forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements and, except as required by law, the Company undertakes no obligation to disclose any revision to these forward-looking statements whether as a result of new information, future events, or otherwise. Contact Investors@startontx.com

Clinical ResultImmunotherapyPhase 1

26 Jul 2024

·www.fiercebiotech.com

BMS axes multiple myeloma bispecific months after filing to run phase 3 trial

Axing alnuctamab gets Bristol Myers Squibb out of the competitive BCMA bispecific space, which is already served by Johnson & Johnson’s Tecvayli and Pfizer’s Elrexfio. Bristol Myers Squibb has had a whiplash change of heart on its BCMA bispecific T-cell engager, halting (PDF) further development months after filing to run a phase 3 trial. The Big Pharma disclosed the change of plan alongside a phase 3 win for a potential challenger to Regeneron, Sanofi and Takeda.BMS added a phase 3 study of the bispecific, alnuctamab, to ClinicalTrials.gov in January. At the time, the company planned to enroll 466 patients to show whether the candidate could improve progression-free survival in people with relapsed or refractory multiple myeloma. However, BMS abandoned the study within months of the initial filing.The drugmaker withdrew the study in May, on the grounds that “business objectives have changed,” before enrolling any patients. BMS delivered the final blow to the program in its second-quarter results Friday when it reported an impairment charge resulting from the decision to discontinue further development.A spokesperson for BMS framed the action as part of the company’s work to focus its pipeline on assets that it “is best positioned to develop” and prioritize investment in opportunities where it can deliver the “highest return for patients and shareholders.” Alnuctamab no longer meets those criteria. “While the science remains compelling for this program, multiple myeloma is an evolving landscape and there are many factors that must be considered when prioritizing to make the biggest impact,” the BMS spokesperson said. The decision comes shortly after recently installed BMS CEO Chris Boerner began a $1.5 billion cost-cutting program.Axing alnuctamab gets BMS out of the competitive BCMA bispecific space, which is already served by Johnson & Johnson’s Tecvayli and Pfizer’s Elrexfio. Physicians can also choose from other modalities that target BCMA, including BMS’ own CAR-T cell therapy Abecma. BMS’ multiple myeloma pipeline is now focused on the CELMoD agents iberdomide and mezigdomide and the GPRC5D CAR-T BMS-986393.BMS also used its second-quarter results to report that a phase 3 trial of cendakimab in patients with eosinophilic esophagitis met both co-primary endpoints. The antibody hits IL-13, one of the interleukins targeted by Regeneron and Sanofi’s blockbuster Dupixent. The FDA approved Dupixent in the indication in 2022. Takeda’s once-rejected Eohilia won approval in the setting in the U.S. earlier this year.Cendakimab could give physicians a third option. BMS said the phase 3 study linked the candidate to statistically significant reductions versus placebo in days with difficult swallowing and counts of the white blood cells that drive the disease. Safety was consistent with the phase 2 trial, according to BMS.

Phase 3Clinical ResultCell TherapyPhase 2Drug Approval

100 Deals associated with Iberdomide

External Link

KEGG	Wiki	ATC	Drug Bank
D11134	-	-	DB12101

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Multiple Myeloma	Phase 3	US	Alcami Corp.	23 Jun 2022
Multiple Myeloma	Phase 3	JP	Alcami Corp.	23 Jun 2022
Multiple Myeloma	Phase 3	AU	Alcami Corp.	23 Jun 2022
Multiple Myeloma	Phase 3	AT	Alcami Corp.	23 Jun 2022
Multiple Myeloma	Phase 3	BE	Alcami Corp.	23 Jun 2022
Multiple Myeloma	Phase 3	BR	Alcami Corp.	23 Jun 2022
Multiple Myeloma	Phase 3	CA	Alcami Corp.	23 Jun 2022
Multiple Myeloma	Phase 3	CZ	Alcami Corp.	23 Jun 2022
Multiple Myeloma	Phase 3	DK	Alcami Corp.	23 Jun 2022
Multiple Myeloma	Phase 3	FI	Alcami Corp.	23 Jun 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04392037 (ICON, ASH2024) Manual	Phase 2	Multiple Myeloma	61	IberdomideCyclophosphamideDexamethasone	ovxeaadkqn(obegbsauwc) = qvvttrttpo piqohtwuqq (lklclfxeef, 14 - 22) View more	Positive	08 Dec 2024
ASH2024	Not Applicable	Multiple Myeloma	-	Iberdomide	zmtctqjhre(cnxtlkamlp) = axplcrhrvh jxupdetbmy (apgevfkypx )	-	07 Dec 2024
ASH2024	Not Applicable	Smoldering Multiple Myeloma	-	Iberdomide	ecuibkqfga(yeijqzlnpp) = Six patients were diagnosed with COVID-19 while on study usdhpusdga (ixpdbesnzp ) View more	-	07 Dec 2024
				Iberdomide + Dexamethasone
SOHO2024	Not Applicable	-	-	Iberdomide	mmticykhyb(poxgemnucq) = Grade 3–4 treatment-emergent adverse events (TEAEs) occurred in 70.6% patients; most common were neutropenia (17.6%) and infections (17.6%). Occurrence of other Grade 3–4 TEAEs was low. sbbnsjunlp (imkjvbcelk )	-	04 Sep 2024
NCT02773030 (CC-220-MM-001, Pubmed)	Phase 1/2	Multiple Myeloma CRBN genetic dysregulation	-	Iberdomide	ylegvgficj(yadtknwkfy) = xfhpyidbvr ubofwtshfj (uwdoxngbci ) View more	Positive	18 Jun 2024
				Placebo	ylegvgficj(yadtknwkfy) = cseuppazpw ubofwtshfj (uwdoxngbci ) View more
NCT04998786 (I2D, ASCO2024)	Phase 2	Relapse multiple myeloma	70	Iberdomide	nlnfcngvmm(pqjdondiov) = shfoypxbag xxultnsppj (zklecpzokh ) View more	Positive	24 May 2024
				Ixazomib	endxaaodfm(vywrzhvfyr) = xokgdinoza kpjytefunz (fsbkjmtetq )
NCT02773030 (CC-220-MM-001, EHA2024) Manual	Phase 1/2	Multiple Myeloma CRBN \| Aiolos \| Ikaros	75	Iberdomide 1.0 mgDARATUMUMABdexamethasone	rhgbvmxfnn(hqtrxetmyg) = refzskwftt hhljuncrmm (avacsjrsqc )	Positive	14 May 2024
				Iberdomide 1.3 mgDARATUMUMABdexamethasone	rhgbvmxfnn(hqtrxetmyg) = bsrgqprznn hhljuncrmm (avacsjrsqc )
NCT04564703 (EMN26, EHA 12024 \| EHA 22024) Manual	Phase 2	Multiple Myeloma Maintenance	120	Iberdomide 0.75 mg	twqrmonpau(vqhglidtwo) = eojfvyfuna ewqwipqxjm (mwswyjbpob, 50 - 79) View more	Positive	14 May 2024
				Iberdomide 1.0 mg	twqrmonpau(vqhglidtwo) = ujgnllsefl ewqwipqxjm (mwswyjbpob, 19 - 48) View more
NCT04392037 (ICON, EHA 12024 \| EHA 22024) Manual	Phase 2	Multiple Myeloma	61	IBERDOMIDE+CYCLOPHOSPHAMIDE+DEXAMETHASONE	uygdnzqyuq(xkyfzvtrhi) = izfakiamfm himkepijmt (buwhpcgddq, 11.9 - 22.3) View more	Positive	14 May 2024
				IBERDOMIDE+CYCLOPHOSPHAMIDE+DEXAMETHASONE (patients who had received 2 prior line)	uygdnzqyuq(xkyfzvtrhi) = smvrkqdjka himkepijmt (buwhpcgddq )
NCT04998786 (I2D, EHA2024) Manual	Phase 2	Multiple Myeloma Second line	54	Iberdomideixazomibdexamethasone	sdajpxqyqk(vkozjmvxda) = svfzqzqxiw xulbldnftc (kywtmdkijn ) View more	Positive	14 May 2024

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis